Brandon Capital leads $14m investment to develop new cancer drug
Brandon Capital's site announces it led $14m for Amaroq Therapeutics, an Otago spinout developing RNA-based cancer treatments — the firm's first deal as a government-backed incubator. The piece also recalls Kea Therapeutics' shutdown.